文献速递其他结缔组织病

青少年起病混合性结缔组织病:多中心回顾性队列研究

Juvenile-onset mixed connective tissue disease: A multicenter retrospective cohort study.
PubMed 文献 · Semin Arthritis Rheum · 2025-12-11

jMCTD临床表现与成人相似但肿胀手指较少,缓解率更高(61.7% vs 44.0%),但初始激素剂量及甲氨蝶呤、利妥昔单抗使用更多。

要点

  • jMCTD患者肿胀手指较aMCTD少见(p<0.0001)。
  • jMCTD缓解率61.7%,高于aMCTD的44.0%(p<0.05)。
  • jMCTD初始激素剂量及甲氨蝶呤、利妥昔单抗使用多于aMCTD。

核心结论

  • jMCTD与aMCTD临床特征相似,但肿胀手指较少,缓解率更高,治疗强度更大。

主要发现

  • 44例(93.6%)符合Sharp或Kasukawa诊断标准。
  • jMCTD患者肿胀手指较aMCTD少见(p<0.0001)。
  • 中位随访9.8(6.6-16.2)年后,29例(61.7%)jMCTD缓解,aMCTD为62例(44.0%)(p<0.05)。
  • 36%的jMCTD进展为其他CTD(aMCTD为30.5%,p=0.5),主要为SLE;11例(23.4%)发生ILD,2例(4.3%)发生PAH,1例(2.1%)死亡。

关键数值与推荐

  • jMCTD初始激素剂量为30(20-60)mg/天,aMCTD为15(10-35)mg/天(p=0.02)。
  • jMCTD累积接受糖皮质激素80.9%、羟氯喹95.7%、免疫抑制剂93.6%。
  • jMCTD较aMCTD更频繁使用甲氨蝶呤和利妥昔单抗(p=0.01)。

临床怎么用

  • jMCTD诊断可依据Sharp或Kasukawa标准,需注意与aMCTD表现差异(如肿胀手指较少)。
  • jMCTD治疗常需糖皮质激素、羟氯喹及免疫抑制剂,初始激素剂量可能较高。
  • jMCTD长期随访需监测疾病进展(如SLE、ILD、PAH)及治疗相关并发症。

局限性

  • 回顾性研究设计可能存在信息偏倚。
  • 来自法国单国队列,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Juvenile-onset mixed connective tissue disease (jMCTD) accounts for 7-23 % of MCTD cases but remains poorly described. We aimed to characterize clinical features, treatments, and outcomes of patients with jMCTD, and compare them to adult-onset MCTD (aMCTD) patients. METHODS: We conducted a multicenter, retrospective, case-control study within the French MCTD cohort. Each jMCTD patient was compared to 3 matched aMCTD patients. RESULTS: Forty-seven jMCTD patients (93.6 % girls; median age at onset 14 [11-16] years) were included. Forty-four (93.6 %) jMCTD patients fulfilled either Sharp or Kasukawa diagnostic criteria. None of them met other diagnostic criteria without fulfilling Sharp or Kasukawa criteria. At diagnosis, jMCTD patients' main manifestations were Raynaud's phenomenon, arthralgia, and myalgia. jMCTD patients had less frequently puffy fingers than aMCTD (p < 0.0001). Cumulatively, jMCTD patients mainly received glucocorticoids (80.9 %), hydroxychloroquine (95.7 %) and immunosuppressants (93.6 %). They received a higher initial dose of glucocorticoids (30 [20-60] mg/day vs. 15 [10-35] mg/day, p = 0.02), and significantly more frequently methotrexate (Methotrexate) and rituximab (p = 0.01) over time compared to aMCTD. After a median follow-up of 9.8 [6.6-16.2] years, 29 (61.7 %) jMCTD patients were in remission (vs. 62 (44.0 %) aMCTD; p < 0.05), 36 % had progressed to another CTD (vs. 30.5 % aMCTD; p = 0.5), mainly systemic lupus erythematosus, 11 (23.4 %) had developed interstitial lung disease, 2 (4.3 %) pulmonary arterial hypertension, and 1 (2.1 %) died. CONCLUSIONS: jMCTD share the same clinical characteristics as aMCTD patients, but less frequently have puffy fingers. Outcomes appear more favorable in jMCTD than aMCTD, with higher remission rates, albeit at the cost of more intensive treatment.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Chevalier K, Bader-Meunier B, Kone-Paut I, et al. Juvenile-onset mixed connective tissue disease: A multicenter retrospective cohort study. Semin Arthritis Rheum. 2025. PMID: 41412094. doi:10.1016/j.semarthrit.2025.152889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。